Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002365148 | SCV002664031 | uncertain significance | Cardiovascular phenotype | 2019-06-26 | criteria provided, single submitter | clinical testing | The p.E23620G variant (also known as c.70859A>G), located in coding exon 178 of the TTN gene, results from an A to G substitution at nucleotide position 70859. The glutamic acid at codon 23620 is replaced by glycine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003138223 | SCV003819683 | uncertain significance | not provided | 2019-06-21 | criteria provided, single submitter | clinical testing | |
Clinical Center for Gene Diagnosis and Therapy, |
RCV003319239 | SCV003932373 | uncertain significance | Primary dilated cardiomyopathy | 2023-06-01 | criteria provided, single submitter | clinical testing |